Meiragtx Holdings ( (MGTX) ) has released its Q3 earnings. Here is a breakdown of the information Meiragtx Holdings presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
MeiraGTx Holdings plc is a clinical-stage genetic medicines company specializing in the development of gene therapies for both rare and common diseases, with a focus on ophthalmology, Parkinson’s disease, and radiation-induced xerostomia. The company has recently announced its third-quarter 2025 financial and operational results, highlighting significant strategic collaborations and advancements in their clinical programs.
In the third quarter of 2025, MeiraGTx entered a strategic collaboration with Eli Lilly to develop genetic medicines in ophthalmology, granting Lilly exclusive rights to the AAV-AIPL1 program for treating Leber congenital amaurosis 4. Additionally, the company made progress in its clinical programs, including a pivotal Phase 2 study for AA V-hAQP1 and plans to initiate a Phase 3 study for AA V-GAD in Parkinson’s disease. MeiraGTx also optimized its riboswitch program for treating leptin deficiency and continued its Specials program for BBS10-associated retinal dystrophy.
Financially, MeiraGTx reported a net loss of $50.5 million for the quarter, with cash and cash equivalents of approximately $14.8 million as of September 30, 2025. The company secured a $75 million upfront payment from Lilly and anticipates additional funding from its collaboration with Hologen AI, which will support its operations into the second half of 2027. Despite a decrease in service revenue and an increase in research and development expenses, MeiraGTx remains focused on advancing its pipeline and achieving regulatory milestones.
Looking ahead, MeiraGTx is poised to leverage its strategic partnerships and proprietary technologies to advance its gene therapy programs. The company’s management remains optimistic about its potential to deliver transformative therapies for patients with unmet medical needs, supported by its robust pipeline and comprehensive manufacturing capabilities.